Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

116 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Protein engineering to increase the potential of a therapeutic antibody Fab for long-acting delivery to the eye.
Tesar D, Luoma J, Wyatt EA, Shi C, Shatz W, Hass PE, Mathieu M, Yi L, Corn JE, Maass KF, Wang K, Dion MZ, Andersen N, Loyet KM, van Lookeren Campagne M, Rajagopal K, Dickmann L, Scheer JM, Kelley RF. Tesar D, et al. Among authors: van lookeren campagne m. MAbs. 2017 Nov/Dec;9(8):1297-1305. doi: 10.1080/19420862.2017.1372078. Epub 2017 Aug 30. MAbs. 2017. PMID: 28854082 Free PMC article.
Structural and functional analysis of a C3b-specific antibody that selectively inhibits the alternative pathway of complement.
Katschke KJ Jr, Stawicki S, Yin J, Steffek M, Xi H, Sturgeon L, Hass PE, Loyet KM, Deforge L, Wu Y, van Lookeren Campagne M, Wiesmann C. Katschke KJ Jr, et al. Among authors: van lookeren campagne m. J Biol Chem. 2009 Apr 17;284(16):10473-9. doi: 10.1074/jbc.M809106200. Epub 2009 Feb 5. J Biol Chem. 2009. PMID: 19196712 Free PMC article.
Inhibiting alternative pathway complement activation by targeting the factor D exosite.
Katschke KJ Jr, Wu P, Ganesan R, Kelley RF, Mathieu MA, Hass PE, Murray J, Kirchhofer D, Wiesmann C, van Lookeren Campagne M. Katschke KJ Jr, et al. Among authors: van lookeren campagne m. J Biol Chem. 2012 Apr 13;287(16):12886-92. doi: 10.1074/jbc.M112.345082. Epub 2012 Feb 23. J Biol Chem. 2012. PMID: 22362762 Free PMC article.
Complement inhibition in cynomolgus monkeys by anti-factor d antigen-binding fragment for the treatment of an advanced form of dry age-related macular degeneration.
Loyet KM, Good J, Davancaze T, Sturgeon L, Wang X, Yang J, Le KN, Wong M, Hass PE, van Lookeren Campagne M, Haughney PC, Morimoto A, Damico-Beyer LA, DeForge LE. Loyet KM, et al. Among authors: van lookeren campagne m. J Pharmacol Exp Ther. 2014 Dec;351(3):527-37. doi: 10.1124/jpet.114.215921. Epub 2014 Sep 17. J Pharmacol Exp Ther. 2014. PMID: 25232192
Population Pharmacokinetics and Pharmacodynamics of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy.
Le KN, Gibiansky L, van Lookeren Campagne M, Good J, Davancaze T, Loyet KM, Morimoto A, Strauss EC, Jin JY. Le KN, et al. Among authors: van lookeren campagne m. CPT Pharmacometrics Syst Pharmacol. 2015 Oct;4(10):595-604. doi: 10.1002/psp4.12031. Epub 2015 Oct 8. CPT Pharmacometrics Syst Pharmacol. 2015. PMID: 26535160 Free PMC article.
A novel inhibitor of the alternative pathway of complement reverses inflammation and bone destruction in experimental arthritis.
Katschke KJ Jr, Helmy KY, Steffek M, Xi H, Yin J, Lee WP, Gribling P, Barck KH, Carano RA, Taylor RE, Rangell L, Diehl L, Hass PE, Wiesmann C, van Lookeren Campagne M. Katschke KJ Jr, et al. Among authors: van lookeren campagne m. J Exp Med. 2007 Jun 11;204(6):1319-25. doi: 10.1084/jem.20070432. Epub 2007 Jun 4. J Exp Med. 2007. PMID: 17548523 Free PMC article.
116 results